KOD (Kodiak Sciences) Days Payable : 0.00 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences Days Payable?

Kodiak Sciences's average Accounts Payable for the three months ended in Sep. 2024 was $2.58 Mil. Kodiak Sciences's Cost of Goods Sold for the three months ended in Sep. 2024 was $0.00 Mil.

The historical rank and industry rank for Kodiak Sciences's Days Payable or its related term are showing as below:

KOD's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 127.37
* Ranked among companies with meaningful Days Payable only.

Kodiak Sciences's Days Payable stayed the same from Sep. 2023 (0.00) to Sep. 2024 (0.00). stayed the same

Kodiak Sciences Days Payable Historical Data

The historical data trend for Kodiak Sciences's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences Days Payable Chart

Kodiak Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Kodiak Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Kodiak Sciences's Days Payable

For the Biotechnology subindustry, Kodiak Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Days Payable distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's Days Payable falls into.

Kodiak Sciences Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Kodiak Sciences's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (9.13	+	13.608)	/	2 )	/	0	*	365
=	11.369					/	0	*	365
=	N/A

Kodiak Sciences's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (1.874	+	3.292)	/	2 )	/	0	*	365 / 4
=	2.583					/	0	*	365 / 4
=	N/A

Kodiak Sciences Days Payable Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

KOD:Mexico K27:Germany

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Executives

John A. Borgeson	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Jason Ehrlich	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth	director, 10 percent owner, officer: Chairman, President and CEO	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang	officer: See Remarks	2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek	director	P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016